Pruritus-Pipeline Review, H2 2016

Pruritus-Pipeline Review, H2 2016

  • Products Id :- GMDHC8405IDB
  • |
  • Pages: 123
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Pruritus-Pipeline Review, H2 2016


Global Markets Direct's, 'Pruritus-Pipeline Review, H2 2016', provides an overview of the Pruritus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Pruritus

The report reviews pipeline therapeutics for Pruritus by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pruritus therapeutics and enlists all their major and minor projects

The report assesses Pruritus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pruritus

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pruritus

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Pruritus Overview 10

Therapeutics Development 11

Pipeline Products for Pruritus-Overview 11

Pipeline Products for Pruritus-Comparative Analysis 12

Pruritus-Therapeutics under Development by Companies 13

Pruritus-Therapeutics under Investigation by Universities/Institutes 15

Pruritus-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Pruritus-Products under Development by Companies 19

Pruritus-Products under Investigation by Universities/Institutes 21

Pruritus-Companies Involved in Therapeutics Development 22

Albireo AB 22

Alveonix AG 23

Amorepacific Corporation 24

Asana BioSciences, LLC 25

Cara Therapeutics, Inc. 26

Chugai Pharmaceutical Co., Ltd. 27

Creabilis SA 28

ELORAC, Inc. 29

Faes Farma, S.A. 30

GlaxoSmithKline Plc 31

Hydra Biosciences, Inc. 32

LEO Pharma A/S 33

Merck & Co., Inc. 34

NeRRe Therapeutics Ltd 35

Nippon Shinyaku Co., Ltd. 36

Patara Pharma, Inc. 37

Phosphagenics Limited 38

RDD Pharma Ltd. 39

Sanwa Kagaku Kenkyusho Co., Ltd. 40

Shionogi & Co., Ltd. 41

Sumitomo Dainippon Pharma Co., Ltd. 42

Teikoku Pharma USA, Inc. 43

Tioga Pharmaceuticals, Inc. 44

Trevi Therapeutics, Inc. 45

Vanda Pharmaceuticals Inc. 46

Pruritus-Therapeutics Assessment 47

Assessment by Monotherapy Products 47

Assessment by Target 48

Assessment by Mechanism of Action 50

Assessment by Route of Administration 53

Assessment by Molecule Type 55

Drug Profiles 57

A-4250-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

aprepitant-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

asimadoline-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

ASN-008-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Ax-10-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Ax-8-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

bilastine-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

cromolyn sodium-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

CT-327-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

CT-340-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

desloratadine-Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

difelikefalin-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

GSK-2330672-Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

lidocaine hydrochloride-Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

nalbuphine hydrochloride ER-Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

naloxone hydrochloride-Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

nemolizumab-Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

NS-141-Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

orvepitant maleate-Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

PAC-14028-Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

Peptides to Target TRPV1 for Pain and Itch-Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

RDD-1609-Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

serlopitant-Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

SK-1405-Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

Small Molecule to Agonize CB2 for Pruritus-Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

Small Molecule to Inhibit Substance P for Pruritus-Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

Small Molecules to Antagonize Mas-Related G-Protein Coupled Receptor for Pruritus-Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis-Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

Small Molecules to Block NaV1.7 Channel for Pain, Ocular Pain and Pruritus-Drug Profile 103

Product Description 103

Mechanism Of Action 103

R&D Progress 103

TPU-010-Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

tradipitant-Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

Pruritus-Dormant Projects 107

Pruritus-Discontinued Products 109

Pruritus-Product Development Milestones 110

Featured News & Press Releases 110

Jun 09, 2016: Cara Therapeutics to Present Preclinical Data at June Medical Meetings 110

Feb 18, 2016: Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine 32nd Annual Meeting 110

Oct 26, 2015: Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference 111

Sep 09, 2015: Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative Pain 112

Jun 11, 2015: Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis 112

May 12, 2015: Cara Therapeutics provides update on its Phase 3 Program for I.V. CR845 113

Apr 15, 2015: Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids 114

Mar 19, 2015: Creabilis' CT327 Phase 2b Data Published in Acta Dermato-Venereologica, Strengthens Scientific Advisory Board 114

Mar 04, 2015: Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 115

Jan 12, 2015: Creabilis Receives Positive Feedback on CT327 from US FDA, Providing Clear Path to Registration 117

Dec 17, 2014: Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients 117

Dec 17, 2014: Velocity Pharmaceutical Development and Tigercat Pharma Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 118

Aug 06, 2014: Cara Therapeutics Initiates Proof-of-Concept Phase II Trial of I.V. CR845 in Uremic Pruritus 119

Mar 21, 2014: Creabilis to Present CT327 Phase 2b Data at American Academy of Dermatology Annual Meeting 119

Jan 23, 2014: Start of Phase II study of neurokinin-1 receptor antagonist orvepitant for intense pruritus induced by epidermal growth factor receptor inhibitors 120

Appendix 122

Methodology 122

Coverage 122

Secondary Research 122

Primary Research 122

Expert Panel Validation 122

Contact Us 122

Disclaimer 123

List of Figures

Number of Products under Development for Pruritus, H2 2016 11

Number of Products under Development for Pruritus-Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Products, H2 2016 18

Assessment by Monotherapy Products, H2 2016 47

Number of Products by Top 10 Targets, H2 2016 48

Number of Products by Stage and Top 10 Targets, H2 2016 48

Number of Products by Top 10 Mechanism of Actions, H2 2016 50

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 50

Number of Products by Routes of Administration, H2 2016 53

Number of Products by Stage and Routes of Administration, H2 2016 53

Number of Products by Molecule Types, H2 2016 55

Number of Products by Stage and Molecule Types, H2 2016 55

List of Tables

Number of Products under Development for Pruritus, H2 2016 11

Number of Products under Development for Pruritus-Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Development by Companies, H2 2016 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Products under Investigation by Universities/Institutes, H2 2016 21

Pruritus-Pipeline by Albireo AB, H2 2016 22

Pruritus-Pipeline by Alveonix AG, H2 2016 23

Pruritus-Pipeline by Amorepacific Corporation, H2 2016 24

Pruritus-Pipeline by Asana BioSciences, LLC, H2 2016 25

Pruritus-Pipeline by Cara Therapeutics, Inc., H2 2016 26

Pruritus-Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016 27

Pruritus-Pipeline by Creabilis SA, H2 2016 28

Pruritus-Pipeline by ELORAC, Inc., H2 2016 29

Pruritus-Pipeline by Faes Farma, S.A., H2 2016 30

Pruritus-Pipeline by GlaxoSmithKline Plc, H2 2016 31

Pruritus-Pipeline by Hydra Biosciences, Inc., H2 2016 32

Pruritus-Pipeline by LEO Pharma A/S, H2 2016 33

Pruritus-Pipeline by Merck & Co., Inc., H2 2016 34

Pruritus-Pipeline by NeRRe Therapeutics Ltd, H2 2016 35

Pruritus-Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 36

Pruritus-Pipeline by Patara Pharma, Inc., H2 2016 37

Pruritus-Pipeline by Phosphagenics Limited, H2 2016 38

Pruritus-Pipeline by RDD Pharma Ltd., H2 2016 39

Pruritus-Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016 40

Pruritus-Pipeline by Shionogi & Co., Ltd., H2 2016 41

Pruritus-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 42

Pruritus-Pipeline by Teikoku Pharma USA, Inc., H2 2016 43

Pruritus-Pipeline by Tioga Pharmaceuticals, Inc., H2 2016 44

Pruritus-Pipeline by Trevi Therapeutics, Inc., H2 2016 45

Pruritus-Pipeline by Vanda Pharmaceuticals Inc., H2 2016 46

Assessment by Monotherapy Products, H2 2016 47

Number of Products by Stage and Target, H2 2016 49

Number of Products by Stage and Mechanism of Action, H2 2016 51

Number of Products by Stage and Route of Administration, H2 2016 54

Number of Products by Stage and Molecule Type, H2 2016 56

Pruritus-Dormant Projects, H2 2016 107

Pruritus-Dormant Projects (Contd..1), H2 2016 108

Pruritus-Discontinued Products, H2 2016 109

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Albireo AB

Alveonix AG

Amorepacific Corporation

Asana BioSciences, LLC

Cara Therapeutics, Inc.

Chugai Pharmaceutical Co., Ltd.

Creabilis SA


Faes Farma, S.A.

GlaxoSmithKline Plc

Hydra Biosciences, Inc.

LEO Pharma A/S

Merck & Co., Inc.

NeRRe Therapeutics Ltd

Nippon Shinyaku Co., Ltd.

Patara Pharma, Inc.

Phosphagenics Limited

RDD Pharma Ltd.

Sanwa Kagaku Kenkyusho Co., Ltd.

Shionogi & Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Teikoku Pharma USA, Inc.

Tioga Pharmaceuticals, Inc.

Trevi Therapeutics, Inc.

Vanda Pharmaceuticals Inc.

Pruritus Therapeutic Products under Development, Key Players in Pruritus Therapeutics, Pruritus Pipeline Overview, Pruritus Pipeline, Pruritus Pipeline Assessment

select a license

Single User License
USD 2000 INR 135460
Site License
USD 4000 INR 270920
Corporate User License
USD 6000 INR 406380



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]